ENGINEERING NATURE’S OWN DELIVERY VEHICLE FOR POWERFUL ANTI-CANCER THERAPY

Tavec is developing the next-generation of potent anti-cancer gene therapies using the power of injectable, miRNA loaded exosomes.

Learn More →

Recent News

10May

TAVEC has received seed funding from Sanderling Ventures

The ability to penetrate the dense structure of solid tumors has been presented a remarkably difficult for treating these tumors. Tavec’s exosome mediated technology enables.. Read More →
18Apr

THERILLIA acquires TAVEC Pharmaceutical and moves it to Montreal

Therillia Development Co., a Montreal-based subsidiary of Sanderling Ventures Canada, an investor in early-stage biotech companies, has acquired TAVEC Pharmaceuticals, the leading therapeutic exosome company.. Read More →